Core Viewpoint - New Fortress Energy Inc. is under investigation for potential securities fraud and unlawful business practices following a significant decline in its financial performance in Q1 2025 [1][2]. Financial Performance - New Fortress reported total revenue of $470.5 million for Q1 2025, a decrease from $690.3 million in Q1 2024, representing a decline of approximately 31.8% [2]. - The company experienced a net loss of $197.4 million, or $0.73 per share, compared to a net income of $56.7 million, or $0.26 per share, in the same period of the previous year [2]. Stock Market Reaction - Following the release of the disappointing financial results, New Fortress's stock price fell by $4.27 per share, or 62.98%, closing at $4.27 per share on May 15, 2025 [3].

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of EchoStar Corporation regarding potential securities fraud or unlawful business practices by the company and its officers [1] - The Federal Communications Commission (FCC) is investigating EchoStar's compliance with federal requirements for building a nationwide 5G network for its Boost Mobile subsidiary, which has faced delays [2] - Following the FCC's announcement, EchoStar's stock price dropped by $4.01 per share, a decline of 16.58%, closing at $20.18 per share on May 12, 2025 [2] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - A class action securities lawsuit has been filed against Solaris Energy Infrastructure, Inc. due to alleged securities fraud affecting investors between July 9, 2024, and March 17, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Solaris Energy Infrastructure, Inc. made false statements and concealed critical information regarding its acquisition of Mobile Energy Rentals LLC (MER), including MER's lack of corporate history in mobile turbine leasing and its non-diversified earnings stream [3]. - It is alleged that MER's co-owner has a criminal background associated with turbine-related fraud, which misled investors about the commercial prospects of the acquisition [3]. - The complaint also states that Solaris inflated its profitability metrics by failing to properly depreciate its turbines, leading to materially misleading statements about the company's business and operations [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until May 27, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating a no-cost participation model [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Solaris Energy Infrastructure, Inc. ("Solaris Energy Infrastructure, Inc." or the "Company") (NYSE: SEI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Solaris Energy Infrastructure, Inc. investors who were adversely affected by alleged securities fraud between July 9, 2024 and March 17, 2025. Follow the link below to get more information and be contacted by a memb ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. following disappointing financial results for Q1 2025, which led to a significant drop in the company's stock price [1][3]. Financial Performance - Globus Medical reported non-GAAP earnings per share of $0.68 for Q1 2025, missing consensus estimates by $0.06 [3]. - The company's revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price decreased by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to several factors, including softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Metallus Inc. and its officers or directors, following disappointing financial results that led to a significant drop in the company's stock price [1][3]. Financial Performance - On May 8, 2025, Metallus reported non-GAAP earnings per share of $0.07 for the first quarter of 2025, which was $0.05 below consensus estimates [3]. - The CEO of Metallus indicated that the company experienced volatility in the defense supply chain due to customer manufacturing start-up challenges during the first quarter [3]. - Following the earnings announcement, Metallus's stock price decreased by $1.48, or 11.31%, closing at $11.61 per share on May 9, 2025 [3]. Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Metallus regarding possible securities fraud or other unlawful business practices [1].

NEW YORK, May 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BigBear.ai Holdings, Inc. (NYSE: BBAI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in BigBear.ai, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bigbearai-holdings-inc. Investors have until June 10, 2025, to ask the Court to be a ...

NEW YORK, May 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Diversified Holdings and Compass Group Diversified Holdings, LLC (NYSE: CODI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Compass you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/compass-diversified-holdings. Investors h ...

NEW YORK, May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Companies, Inc. ("Rocket Companies" or the "Company") (NYSE: RKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket Companies investors who were adversely affected by alleged securities fraud between March 29, 2021 and April 1, 2021. Follow the link below to get more information and be contacted by a member of our team:https://www.zlk.com/pslra-1/rocket-compa ...

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across more than 165 countries and territories [3]. - The complaint claims that Viatris misrepresented the condition of its facilities, stating they were in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter issued by the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results released on February 27, 2025, Viatris disclosed that the negative impact from the Indore facility's inspection would lower 2025 revenue by approximately $500 million and earnings from operations by approximately $385 million [5]. - Following this announcement, Viatris's stock price fell about 15%, dropping from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].